Johnson & Johnson Submits Emergency Use Authorization Amendment to FDA Supporting COVID-19 Booster Vaccine

The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson's single-shot vaccine administered 56 days after the primary dose provided 94% protection ...

from Google Alert - Business https://ift.tt/3lkuU7n
The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson's single-shot vaccine administered 56 days after the primary dose provided 94% protection ... https://ift.tt/eA8V8J

Comments

Popular posts from this blog

Jobless Rate Drops

Electrolytic Fixed Power Capacitors Market Competitive intelligence & regional outlook 2020

USU project among finalists for $3 million solar energy tech prize